Selected research
Market Analysis & Forecast
Global Anti-TIGIT Antibody Market Analysis and Forecast 2026-2032
Market perspective
The global Anti-TIGIT Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Anti-TIGIT Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Anti-TIGIT Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Anti-TIGIT Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Anti-TIGIT Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Anti-TIGIT Antibody include Arcus, Astellas, BMS, Compugen, Gilead Sciences, Mereo BioPharma, Seattle Genetics, AstraZeneca and BeiGene, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Anti-TIGIT Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Anti-TIGIT Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-TIGIT Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-TIGIT Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-TIGIT Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti-TIGIT Antibody revenue, projected growth trends, production technology, application and end-user industry.
Anti-TIGIT Antibody Segment by Company
Arcus
Astellas
BMS
Compugen
Gilead Sciences
Mereo BioPharma
Seattle Genetics
AstraZeneca
BeiGene
Hengrui Medicine
Junshi Biosciences
Roche
Merck
Innovent Biologics
Anti-TIGIT Antibody Segment by Type
Monotherapy
Combination Therapy
Anti-TIGIT Antibody Segment by Application
Cell Carcinoma
Solid Tumor
Anti-TIGIT Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-TIGIT Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-TIGIT Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-TIGIT Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Anti-TIGIT Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Anti-TIGIT Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-TIGIT Antibody revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Monotherapy
- Combination Therapy
Applications
- Cell Carcinoma
- Solid Tumor
Companies covered
- Arcus
- Astellas
- BMS
- Compugen
- Gilead Sciences
- Mereo BioPharma
- Seattle Genetics
- AstraZeneca
- BeiGene
- Hengrui Medicine
- Junshi Biosciences
- Roche
- Merck
- Innovent Biologics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Anti-TIGIT Antibody Market by Type
- 1.2.1 Global Anti-TIGIT Antibody Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Monotherapy
- 1.2.3 Combination Therapy
- 1.3 Anti-TIGIT Antibody Market by Application
- 1.3.1 Global Anti-TIGIT Antibody Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Cell Carcinoma
- 1.3.3 Solid Tumor
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Anti-TIGIT Antibody Market Dynamics
- 2.1 Anti-TIGIT Antibody Industry Trends
- 2.2 Anti-TIGIT Antibody Industry Drivers
- 2.3 Anti-TIGIT Antibody Industry Opportunities and Challenges
- 2.4 Anti-TIGIT Antibody Industry Restraints
3 Global Growth Perspective
- 3.1 Global Anti-TIGIT Antibody Market Perspective (2021-2032)
- 3.2 Global Anti-TIGIT Antibody Growth Trends by Region
- 3.2.1 Global Anti-TIGIT Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Anti-TIGIT Antibody Market Size by Region (2021-2026)
- 3.2.3 Global Anti-TIGIT Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Anti-TIGIT Antibody Revenue by Players
- 4.1.1 Global Anti-TIGIT Antibody Revenue by Players (2021-2026)
- 4.1.2 Global Anti-TIGIT Antibody Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Anti-TIGIT Antibody Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Anti-TIGIT Antibody Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Anti-TIGIT Antibody Key Players Headquarters & Area Served
- 4.4 Global Anti-TIGIT Antibody Players, Product Type & Application
- 4.5 Global Anti-TIGIT Antibody Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Anti-TIGIT Antibody Market CR5 and HHI
- 4.6.3 2025 Anti-TIGIT Antibody Tier 1, Tier 2, and Tier 3
5 Anti-TIGIT Antibody Market Size by Type
- 5.1 Global Anti-TIGIT Antibody Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Anti-TIGIT Antibody Revenue by Type (2021-2032)
- 5.3 Global Anti-TIGIT Antibody Revenue Market Share by Type (2021-2032)
6 Anti-TIGIT Antibody Market Size by Application
- 6.1 Global Anti-TIGIT Antibody Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Anti-TIGIT Antibody Revenue by Application (2021-2032)
- 6.3 Global Anti-TIGIT Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Arcus
- 7.1.1 Arcus Company Information
- 7.1.2 Arcus Business Overview
- 7.1.3 Arcus Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.1.4 Arcus Anti-TIGIT Antibody Product Portfolio
- 7.1.5 Arcus Recent Developments
- 7.2 Astellas
- 7.2.1 Astellas Company Information
- 7.2.2 Astellas Business Overview
- 7.2.3 Astellas Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.2.4 Astellas Anti-TIGIT Antibody Product Portfolio
- 7.2.5 Astellas Recent Developments
- 7.3 BMS
- 7.3.1 BMS Company Information
- 7.3.2 BMS Business Overview
- 7.3.3 BMS Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.3.4 BMS Anti-TIGIT Antibody Product Portfolio
- 7.3.5 BMS Recent Developments
- 7.4 Compugen
- 7.4.1 Compugen Company Information
- 7.4.2 Compugen Business Overview
- 7.4.3 Compugen Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.4.4 Compugen Anti-TIGIT Antibody Product Portfolio
- 7.4.5 Compugen Recent Developments
- 7.5 Gilead Sciences
- 7.5.1 Gilead Sciences Company Information
- 7.5.2 Gilead Sciences Business Overview
- 7.5.3 Gilead Sciences Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.5.4 Gilead Sciences Anti-TIGIT Antibody Product Portfolio
- 7.5.5 Gilead Sciences Recent Developments
- 7.6 Mereo BioPharma
- 7.6.1 Mereo BioPharma Company Information
- 7.6.2 Mereo BioPharma Business Overview
- 7.6.3 Mereo BioPharma Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.6.4 Mereo BioPharma Anti-TIGIT Antibody Product Portfolio
- 7.6.5 Mereo BioPharma Recent Developments
- 7.7 Seattle Genetics
- 7.7.1 Seattle Genetics Company Information
- 7.7.2 Seattle Genetics Business Overview
- 7.7.3 Seattle Genetics Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.7.4 Seattle Genetics Anti-TIGIT Antibody Product Portfolio
- 7.7.5 Seattle Genetics Recent Developments
- 7.8 AstraZeneca
- 7.8.1 AstraZeneca Company Information
- 7.8.2 AstraZeneca Business Overview
- 7.8.3 AstraZeneca Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.8.4 AstraZeneca Anti-TIGIT Antibody Product Portfolio
- 7.8.5 AstraZeneca Recent Developments
- 7.9 BeiGene
- 7.9.1 BeiGene Company Information
- 7.9.2 BeiGene Business Overview
- 7.9.3 BeiGene Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.9.4 BeiGene Anti-TIGIT Antibody Product Portfolio
- 7.9.5 BeiGene Recent Developments
- 7.10 Hengrui Medicine
- 7.10.1 Hengrui Medicine Company Information
- 7.10.2 Hengrui Medicine Business Overview
- 7.10.3 Hengrui Medicine Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.10.4 Hengrui Medicine Anti-TIGIT Antibody Product Portfolio
- 7.10.5 Hengrui Medicine Recent Developments
- 7.11 Junshi Biosciences
- 7.11.1 Junshi Biosciences Company Information
- 7.11.2 Junshi Biosciences Business Overview
- 7.11.3 Junshi Biosciences Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.11.4 Junshi Biosciences Anti-TIGIT Antibody Product Portfolio
- 7.11.5 Junshi Biosciences Recent Developments
- 7.12 Roche
- 7.12.1 Roche Company Information
- 7.12.2 Roche Business Overview
- 7.12.3 Roche Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.12.4 Roche Anti-TIGIT Antibody Product Portfolio
- 7.12.5 Roche Recent Developments
- 7.13 Merck
- 7.13.1 Merck Company Information
- 7.13.2 Merck Business Overview
- 7.13.3 Merck Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.13.4 Merck Anti-TIGIT Antibody Product Portfolio
- 7.13.5 Merck Recent Developments
- 7.14 Innovent Biologics
- 7.14.1 Innovent Biologics Company Information
- 7.14.2 Innovent Biologics Business Overview
- 7.14.3 Innovent Biologics Anti-TIGIT Antibody Revenue and Gross Margin (2021-2026)
- 7.14.4 Innovent Biologics Anti-TIGIT Antibody Product Portfolio
- 7.14.5 Innovent Biologics Recent Developments
8 North America
- 8.1 North America Anti-TIGIT Antibody Revenue (2021-2032)
- 8.2 North America Anti-TIGIT Antibody Revenue by Type (2021-2032)
- 8.2.1 North America Anti-TIGIT Antibody Revenue by Type (2021-2026)
- 8.2.2 North America Anti-TIGIT Antibody Revenue by Type (2027-2032)
- 8.3 North America Anti-TIGIT Antibody Revenue Share by Type (2021-2032)
- 8.4 North America Anti-TIGIT Antibody Revenue by Application (2021-2032)
- 8.4.1 North America Anti-TIGIT Antibody Revenue by Application (2021-2026)
- 8.4.2 North America Anti-TIGIT Antibody Revenue by Application (2027-2032)
- 8.5 North America Anti-TIGIT Antibody Revenue Share by Application (2021-2032)
- 8.6 North America Anti-TIGIT Antibody Revenue by Country
- 8.6.1 North America Anti-TIGIT Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Anti-TIGIT Antibody Revenue by Country (2021-2026)
- 8.6.3 North America Anti-TIGIT Antibody Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Anti-TIGIT Antibody Revenue (2021-2032)
- 9.2 Europe Anti-TIGIT Antibody Revenue by Type (2021-2032)
- 9.2.1 Europe Anti-TIGIT Antibody Revenue by Type (2021-2026)
- 9.2.2 Europe Anti-TIGIT Antibody Revenue by Type (2027-2032)
- 9.3 Europe Anti-TIGIT Antibody Revenue Share by Type (2021-2032)
- 9.4 Europe Anti-TIGIT Antibody Revenue by Application (2021-2032)
- 9.4.1 Europe Anti-TIGIT Antibody Revenue by Application (2021-2026)
- 9.4.2 Europe Anti-TIGIT Antibody Revenue by Application (2027-2032)
- 9.5 Europe Anti-TIGIT Antibody Revenue Share by Application (2021-2032)
- 9.6 Europe Anti-TIGIT Antibody Revenue by Country
- 9.6.1 Europe Anti-TIGIT Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Anti-TIGIT Antibody Revenue by Country (2021-2026)
- 9.6.3 Europe Anti-TIGIT Antibody Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China Anti-TIGIT Antibody Revenue (2021-2032)
- 10.2 China Anti-TIGIT Antibody Revenue by Type (2021-2032)
- 10.2.1 China Anti-TIGIT Antibody Revenue by Type (2021-2026)
- 10.2.2 China Anti-TIGIT Antibody Revenue by Type (2027-2032)
- 10.3 China Anti-TIGIT Antibody Revenue Share by Type (2021-2032)
- 10.4 China Anti-TIGIT Antibody Revenue by Application (2021-2032)
- 10.4.1 China Anti-TIGIT Antibody Revenue by Application (2021-2026)
- 10.4.2 China Anti-TIGIT Antibody Revenue by Application (2027-2032)
- 10.5 China Anti-TIGIT Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Anti-TIGIT Antibody Revenue (2021-2032)
- 11.2 Asia Anti-TIGIT Antibody Revenue by Type (2021-2032)
- 11.2.1 Asia Anti-TIGIT Antibody Revenue by Type (2021-2026)
- 11.2.2 Asia Anti-TIGIT Antibody Revenue by Type (2027-2032)
- 11.3 Asia Anti-TIGIT Antibody Revenue Share by Type (2021-2032)
- 11.4 Asia Anti-TIGIT Antibody Revenue by Application (2021-2032)
- 11.4.1 Asia Anti-TIGIT Antibody Revenue by Application (2021-2026)
- 11.4.2 Asia Anti-TIGIT Antibody Revenue by Application (2027-2032)
- 11.5 Asia Anti-TIGIT Antibody Revenue Share by Application (2021-2032)
- 11.6 Asia Anti-TIGIT Antibody Revenue by Country
- 11.6.1 Asia Anti-TIGIT Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Anti-TIGIT Antibody Revenue by Country (2021-2026)
- 11.6.3 Asia Anti-TIGIT Antibody Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Anti-TIGIT Antibody Revenue (2021-2032)
- 12.2 SAMEA Anti-TIGIT Antibody Revenue by Type (2021-2032)
- 12.2.1 SAMEA Anti-TIGIT Antibody Revenue by Type (2021-2026)
- 12.2.2 SAMEA Anti-TIGIT Antibody Revenue by Type (2027-2032)
- 12.3 SAMEA Anti-TIGIT Antibody Revenue Share by Type (2021-2032)
- 12.4 SAMEA Anti-TIGIT Antibody Revenue by Application (2021-2032)
- 12.4.1 SAMEA Anti-TIGIT Antibody Revenue by Application (2021-2026)
- 12.4.2 SAMEA Anti-TIGIT Antibody Revenue by Application (2027-2032)
- 12.5 SAMEA Anti-TIGIT Antibody Revenue Share by Application (2021-2032)
- 12.6 SAMEA Anti-TIGIT Antibody Revenue by Country
- 12.6.1 SAMEA Anti-TIGIT Antibody Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Anti-TIGIT Antibody Revenue by Country (2021-2026)
- 12.6.3 SAMEA Anti-TIGIT Antibody Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst